ProCE Banner Activity

CD19 CAR-T Cells Induce Durable Responses in Relapsed/Refractory CD19-Positive Lymphomas

Slideset Download
Conference Coverage
Overall response rates of 50% in DLBCL and 100% in follicular lymphoma; all CRs maintained as of last analysis.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation